Logo image
Type 3 hybrid effectiveness-implementation study implementing and evaluating the Comprehensive High-dose Aphasia Treatment (CHAT) programme in Australian rehabilitation services: a protocol
Journal article   Open access   Peer reviewed

Type 3 hybrid effectiveness-implementation study implementing and evaluating the Comprehensive High-dose Aphasia Treatment (CHAT) programme in Australian rehabilitation services: a protocol

Marie-Pier McSween, Jade K Dignam, Kirstine Shrubsole, Rachel Levine, Emma Power, Natasha A Lannin, Sarah J Wallace, Dominique A Cadilhac, Monique F Kilkenny, Annie J Hill, …
BMJ Open, Vol.16(5), pp.1-10
18/05/2026
PMID: 42150834
pdf
Type 3 hybrid effectiveness-implementation study469.07 kBDownloadView
Published (Version of record) Open CC BY V4.0
url
Type 3 hybrid effectiveness-implementation studyView
Published (Version of record) Open CC BY V4.0

Related links

Metrics

1 Record Views

Abstract

Implementation Science Rehabilitation medicine Speech pathology Stroke
Introduction The Comprehensive High-dose Aphasia Treatment (CHAT) programme is an intensive comprehensive aphasia programme, which aims to address evidence-practice gaps in aphasia rehabilitation where there are known barriers to service delivery requiring implementation strategies. The aims of this study are to (1) evaluate the clinical implementation of the CHAT programme, (2) assess the clinical effectiveness of CHAT compared with usual care in rehabilitation services and (3) determine whether the real-world implementation of CHAT compared with usual care is cost-effective. Methods and analysis Four participant groups will be recruited across six hospital and health services Australia-wide to participate in a type 3 hybrid effectiveness-implementation study: (1) people with aphasia, (2) support persons, (3) treating clinicians and students and (4) clinical stakeholders (eg, managers). This before-and-after study will include three time periods: (1) ‘usual care’ where people with aphasia will receive their usual care aphasia therapy, (2) ‘implementation transition’ where clinicians will be trained to deliver CHAT and (3) ‘intervention implementation’ where people with aphasia will receive the CHAT programme (ie, 50 hours of evidence-based aphasia therapy over 8 weeks). Evidence-based implementation strategies will be used to facilitate implementation within participating rehabilitation services. The primary outcome is delivery of evidence-based aphasia treatment (ie, CHAT) as measured by a composite score of quality indicators. Clinical effectiveness outcomes, measuring change in language impairment, communication effectiveness, confidence and quality of life, and implementation outcomes will also be examined. We will also conduct an embedded mixed-methods process evaluation and economic evaluation. Ethics and dissemination This study has been approved by the Royal Brisbane and Women’s Hospital Human Research Ethics Committee (HREC/2021/QRBW/72154). Outputs will include conference presentations, publications and a training package to optimise implementation of aphasia treatment in rehabilitation service contexts. Registration details Australian New Zealand Clinical Trials Registry (ANZCTR) prospective registration ACTRN12621001765819. Trial registered 23 December 2021. https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=381365&isReview=true.

Details

Logo image